Advances in Pretransplant Donor-Specific Antibody Testing in Solid Organ Transplantation: From Bench to Bedside

REFERENCES

• Irwin M.R., The beginnings of immunogenetics. Immunogenetics 1976; 3(1): 1–13.
   Web of Science ®Google Scholar
• Lefaucheur C., , IgG donor-specific anti-Human HLA antibody subclasses and Kidney allograft antibody-mediated injury. J Am Soc Nephrol 2015.
   Google Scholar
• Visentin J., Guidicelli G., Taupin J.L.. Assessing HLA antibody strength: Have we thought about everything? Am J Transplant 2015;p. n/a-n/a.
   Web of Science ®Google Scholar
• Focosi D., Zucca A., Scatena F.. The role of anti-HLA antibodies in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011;17(11):p. 1585–1588.
   PubMed Web of Science ®Google Scholar
• Wiebe C., Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012;12(5): 1157–1167.
   PubMed Web of Science ®Google Scholar
• Kosmoliaptsis V., Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation. Kidney Int 2014;86(5): 1039–1048.
   PubMed Web of Science ®Google Scholar
• Mengel M., Precision diagnostics in transplantation: From bench to bedside. Am J Transplant 2013;13(3): 562–568.
   PubMed Web of Science ®Google Scholar
• Tait B.D., Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95(1): 19–47.
   PubMed Web of Science ®Google Scholar
• Terasaki P., Serotyping for homotransplantation. XX. Selection of recipients for cadaver donor transplants. N Engl J Med 1968;279(20): 1101–1103.
   PubMed Web of Science ®Google Scholar
• Azocar J., Changes in the expression of HLA and beta 2-microglobulin by cultured lymphoid cells. Hum Immunol 1982;5(4):283–293.
   PubMed Web of Science ®Google Scholar
• Bishara A., Nelken D., Brautbar C. Differential expression of HLA class-I antigens on B and T lymphocytes obtained from human lymphoid tissues. Immunobiology 1988;177(1): 76–81.
   PubMed Web of Science ®Google Scholar
• Praticò-Barbato L., B cell positive cross-match not due to anti-HLA Class I antibodies and first kidney graft outcome. Transpl Immunol 2008;19(3-4): 238–243.
   PubMed Web of Science ®Google Scholar
• Claas F. Clinical relevance of circulating donor-specific HLA antibodies. Curr Opin Organ Transplant 2010;15(4): 462–466.
   PubMed Web of Science ®Google Scholar
• Schwaiger E., Complement component C3 activation: The leading cause of the prozone phenomenon affecting HLA antibody detection on single-antigen beads. Transplantation 2014;97(12): 1279–1285.
   PubMed Web of Science ®Google Scholar
• Schaub S., Determinants of C1q Binding in the Single Antigen Bead Assay. Transplantation 2014.
   PubMedGoogle Scholar
• Kushihata F., Human leukocyte antigen antibodies and human complement activation: Role of IgG subclass, specificity, and cytotoxic potential. Transplantation 2004;78(7): 995–1001.
   PubMed Web of Science ®Google Scholar
• Duquesnoy R.J., Structural aspects of HLA class I epitopes reacting with human monoclonal antibodies in Ig-binding, C1q-binding and lymphocytotoxicity assays. Hum Immunol 2013;74(10): 1271–1279.
   PubMed Web of Science ®Google Scholar
• Liwski R., Lee S., Sperry, R. The antiYhuman globulin enhanced C1qScreen(Tm) assay improves the detection of complement binding donor specific HLA-antibodies (abstract 60-OR). Hum Immunol 2013.
   Google Scholar
• Cooper N.R. The classical complement pathway: Activation and regulation of the first complement component. Adv Immunol 1985;37: 151–216.
   PubMed Web of Science ®Google Scholar
• Muczynski K.A., Normal human kidney HLA-DR-expressing renal microvascular endothelial cells: Characterization, isolation, and regulation of MHC Class II expression. J Am Soc Nephrol 2003;14(5): 1336–1348.
   PubMed Web of Science ®Google Scholar
• Holling T.M., Activated human T cells accomplish MHC Class II expression through T cell-specific occupation of Class II transactivator promoter III. J Immunol 2002;168(2): 763–770.
   PubMed Web of Science ®Google Scholar
• Kwak B.M., F`, The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly 2001;131(3-4): 41–46.
   PubMed Web of Science ®Google Scholar
• Lee S., Qin, H., Benveniste, E. The IFN-gamma-induced transcriptional program of the CIITA gene is inhibited by statins. Eur J Immunol 2008;38(8): 2325–2336.
   PubMed Web of Science ®Google Scholar
• Hershman M., Cheadle W., Wellhausen, S. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. BJS 1990;77: 204–207.
   Web of Science ®Google Scholar
• Otten H., Pretransplant donor-specific HLA Class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012;12(6): 1618–1623.
   PubMed Web of Science ®Google Scholar
• Caro-Oleas J., Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant 2012;27(3): 1231–1238.
   PubMed Web of Science ®Google Scholar
• Lefaucheur C., Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010;21(8): 1398–1406.
   PubMed Web of Science ®Google Scholar
• Zeevi A., The big picture: A case report of antibody mediated rejection and treatment after lung transplantation illustrating the need to correlate laboratory findings with clinical status. Clin Transpl 2013; 399–405.
   PubMedGoogle Scholar
• Reed E.F., Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA-drilling down on key sources of variation. Am J Transplant 2013;13(11):3050–3051.
   PubMed Web of Science ®Google Scholar
• Hancock W., Kraft N., Atkins, R., The immunohistochemical demonstration of major histocompatibility antigens in the human kidney using monoclonal antibodies. Pathology 1982;14(4): 409–414.
   PubMed Web of Science ®Google Scholar
• Hart, D., Localization of HLA-ABC and DR antigens in human kidney. Transplantation 1981;31(6): 428–433.
   PubMed Web of Science ®Google Scholar
• Evans, P., Varying expression of major histocompatibility complex antigens on human renal endothelium and epithelium. Br J Exp Pathol 1985;66(1): 79–87.
   PubMedGoogle Scholar
• Fuggle S., Localization of major histocompatibility complex (HLA-ABC and DR) antigens in 46 kidneys. Differences in HLA-DR staining of tubules among kidneys. Transplantation 1983;35(4): 385–390.
   PubMed Web of Science ®Google Scholar
• Thomas R., HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. Nat Genet 2009;41(12): 1290–1294.
   PubMed Web of Science ®Google Scholar
• Bachelet T., Anti-Cw donor-specific alloantibodies can lead to positive flow cytometry crossmatch and irreversible acute antibody-mediated rejection. Am J Transplant 2011;11(7): 1543–1544.
   PubMed Web of Science ®Google Scholar
• Bosch A., HLA-C antibodies are associated with irreversible rejection in kidney transplantation: shared molecular eplets characterization. Hum Immunol 2014.
   PubMed Web of Science ®Google Scholar
• Chapman J., Hyperacute rejection of a renal allograft in the presence of anti-HLA-Cw5 antibody. Transplantation 1986;42(1): 91–93.
   PubMed Web of Science ®Google Scholar
• Chen G., Tyan D.B., C1q assay for the detection of complement fixing antibody to HLA antigens. Methods Mol Biol 2013;1034: 305–311.
   PubMedGoogle Scholar
• Goral, S., Preformed donor-directed anti-HLA-DP antibodies may be an impediment to successful kidney transplantation. Nephrol Dial Transplant 2008;23(1):390–392.
   PubMed Web of Science ®Google Scholar
• Thaunat O.H.W, Chronic humoral rejection mediated by anti-HLA-DP alloantibodies: Insights into the role of epitope sharing in donor-specific and non-donor specific alloantibodies generation. Transpl Immunol 2009;20(4):209–211.
   PubMed Web of Science ®Google Scholar
• Jolly E.C.E., Preformed donor HLA-DP-specific antibodies mediate acute and chronic antibody-mediated rejection following renal transplantation. Am J Transplant 2012.
   PubMedGoogle Scholar
• Samaniego M., C4d-positive acute antibody-mediated rejection due to anti-HLA-DP antibody: a tale of one patient and a review of the University of Wisconsin experience. Clin Transpl 2006: 503–507.
   PubMedGoogle Scholar
• Qiu, J., , Detection of antibodies to HLA-DP in renal transplant recipients using single antigen beads. Transplantation 2005 80(10): 1511–1513.
   PubMed Web of Science ®Google Scholar
• Cippa P.E., , Late antibody-mediated rejection by de novo donor HLA-DP-specific antibody after renal transplantation: A case report. Hum Immunol 2014.
   PubMedGoogle Scholar
• Mytilineos J., Deufel A., Opelz G. Clinical relevance of HLA-DPB locus matching for cadaver kidney retransplants: a report of the Collaborative Transplant Study. Transplantation 1997;63(9):1351–1354.
   PubMed Web of Science ®Google Scholar
• Laux G., A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation 2003;75(9):1527–1532.
   PubMed Web of Science ®Google Scholar
• Barabanova Y. and Ramon D.T., AR Antibodies against HLA-DQ alpha-chain and their role in organ transplantation. Hum Immunol 2009;70(6):410–412.
   PubMed Web of Science ®Google Scholar
• Fernandes A., Foss M., Donadi E., HLA-DQB1 alleles may influence the surface expression of DQ molecules in lymphomononuclear cells of type 1 diabetes mellitus patients. Scand J Immunol 2004;59(3):305–309.
   PubMed Web of Science ®Google Scholar
• Schwiebert L., Modulation of MHC class II expression in human cells by dexamethasone. Cell Immunol 1995;165(1):12–19.
   PubMed Web of Science ®Google Scholar
• Willicombe M., De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy. Transplantation 2012.
   Google Scholar
• Tambur A.R., Assessing Antibody Strength: Comparison of MFI, C1q, and Titer Information. Am J Transplant 2015;15(9): 2421–2430.
   PubMed Web of Science ®Google Scholar
• Rudy G. Lew A. The nonpolymorphic MHC class II isotype, HLA-DQA2, is expressed on the surface of B lymphoblastoid cells. J Immunol 1997;158(5):2116–2125.
   PubMed Web of Science ®Google Scholar
• Schnaidt M., HLA antibody specification using single-antigen beads—A technical solution for the prozone effect. Transplantation 2011;92(5):510–515.
   PubMed Web of Science ®Google Scholar
• Nakamura M., Probing the normal and autoimmune B cell repertoire with Epstein-Barr virus. Frequency of B cells producing monoreactive high affinity autoantibodies in patients with Hashimoto's disease and systemic lupus erythematosus. J Immunol 1988;141(12):4165–4172.
   PubMed Web of Science ®Google Scholar
• Mouthon L., The self-reactive antibody repertoire of normal human serum IgM is acquired in early childhood and remains conserved throughout life. Scand J Immunol 1996 44(3):243–251.
   PubMed Web of Science ®Google Scholar
• Dighiero G., Thirty-six human monoclonal immunoglobulins with antibody activity against cytoskeleton proteins, thyroglobulin, and native DNA: immunologic studies and clinical correlations. Blood 1983;62(2): 264–270.
   PubMed Web of Science ®Google Scholar
• Steele E., Cunningham A. High proportion of Ig-producing cells making autoantibody in normal mice. Nature 1978;274(5670): 483–484.
   PubMed Web of Science ®Google Scholar
• Hardy R., Rayakawa K. Development and physiology of Ly-1 B and its human homolog, Leu-1 B. Immunol Rev 1986;93: 53–79.
   PubMed Web of Science ®Google Scholar
• Clarke S.H., Arnold L.W. B-1 cell development: Evidence for an uncommitted immunoglobulin (Ig)M +B cell precursor in B-1 cell differentiation. J Exper Med 1998;187(8): 1325–1334.
   PubMed Web of Science ®Google Scholar
• Barbouche R., Spontaneous IgM autoantibody production in vitro by B lymphocytes of normal human neonates. Scand J Immunol 1992;35(6): 659–667.
   PubMed Web of Science ®Google Scholar
• Ailus, K., Palosuo T., IgM class autoantibodies in human cord blood. J. Reprod. Immunol 1995;29:61–67.
   PubMed Web of Science ®Google Scholar
• Fagarasan S., Honjo T. T-independent immune response: New aspects of B cell biology. Science 2000;290(5489): 89–92.
   PubMed Web of Science ®Google Scholar
• Terasaki P., Mottironi V., Barnett, E. Cytotoxins in disease. Autocytotoxins in lupus. N Engl J Med 1970;283(14): 724–728.
   PubMed Web of Science ®Google Scholar
• Winfield J., Nature of cold-reactive antibodies to lymphocyte surface. Artritis Rheum 1975;18:1–8.
   PubMed Web of Science ®Google Scholar
• Gilbreath M., Characterization of cold reactive lymphocytotoxic antibodies in malaria. Clin Exp Immunol 1983;51(2): 232–238.
   PubMed Web of Science ®Google Scholar
• Lobo P. Nature of autolymphocytotoxins present in renal hemodialysis patients: their possible role in controlling alloantibody formation. Transplantation 1981;32:233–237.
   PubMed Web of Science ®Google Scholar
• Lobo P., Surratt P. Studies on the autoantibody to lymphocytes in sarcoidosis. J. Clin. Lab. Immunol 1979;1: 283–288.
   PubMedGoogle Scholar
• Dorsett, B., Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am. J. Med 1985;78: 621–626.
   PubMed Web of Science ®Google Scholar
• Cervenak J., Kiss K., Uher, F., Partial characterization of two lymphocyte-specific natural autoantibodies isolated from newborn mice. Acta Microbiol. Immunol 1999;46:53–62.
   PubMedGoogle Scholar
• Lobo P.I., Naturally occurring IgM anti-leukocyte autoantibodies (IgM-ALA) inhibit T cell activation and chemotaxis. J Immunol 2008;180(3): 1780–1791.
   PubMed Web of Science ®Google Scholar
• Griggi T., Autoantibodies against ganglioside GM3 represents a portion of antilymphocytic antibodies in AIDS patients. Scand. J. Immunol 1994;40: 77–82.
   PubMed Web of Science ®Google Scholar
• Sorice, M., Anti-glycosphingolipid antibodies in HIV infection. AIDS 1991;5: 345–346.
   PubMed Web of Science ®Google Scholar
• Strickler, R., An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4 cells. Nature 1987;327710–713.
   PubMed Web of Science ®Google Scholar
• Warren, R., Specificity of anti-lymphocyte antibodies in sera from patients with AIDS-related complex (ARC) and healthy homosexuals. Clin. Exp. Immunol 1988;73: 168–173.
   PubMed Web of Science ®Google Scholar
• Minota, S., Winfield J. Identification of three major target molecules of IgM antilymphocyte autoantibodies in systemic lupus erythematosus. J Immunol 1987;139(11): 3644–3651.
   PubMed Web of Science ®Google Scholar
• Mimura T., Autoantibodies specific for different isoforms of CD45 in SLE. J Exp Med 1994;172: 653–656.
   Web of Science ®Google Scholar
• Stimmler M.M., Anticardiolipin antibodies in acquired immunodeficiency syndrome. Arch Intern Med 1989;149(8):1833–1835.
   PubMedGoogle Scholar
• Lee J.Y.-Y., Hempel J., Deng J.-S. Anti-adenosine deaminase antibodies in lupus erythematosus. Lupus 2002;11(3):168–174.
   PubMed Web of Science ®Google Scholar
• Mamoune, A., , CD45 autoantibodies mediate neutralization of activated T cells from lupus patients through anergy or apoptosis. Lupus 2000;9(8): 622–631.
   PubMed Web of Science ®Google Scholar
• Williams R., Masur H., Spira, T. Lymphocyte reactive antibodies in acquired immune deficiency syndrome. J. Clin. Immunol 1984;4: 118–123.
   PubMed Web of Science ®Google Scholar
• Griggi T., Autoantibodies against ganglioside GM3 represent a portion of anti-lymphocyte antibodies in AIDS patients. . ,. Scand. J. Immunol 1994;40:77–82.
   Web of Science ®Google Scholar
• Liao J.-J., Immunosuppressive human anti-lymphocyte autoantibodies specific for the type 1 sphingosine 1-phosphate receptor. FASEB J. 2009;23(6):1786–1796.
   PubMed Web of Science ®Google Scholar
• Sharma S., Fingolimod (FTY720): First approved oral therapy for multiple sclerosis. J Pharmacol Pharmacother 2011;2(1):49–51.
   PubMedGoogle Scholar
• Bearden C., Removal of therapeutic anti-lymphocyte antibodies from human sera prior to anti-human leukocyte antibody testing. J Immunol Methods 2005;300(1-2): 192–199.
   PubMed Web of Science ®Google Scholar
• Gloor J., The effect of antithymocyte globulin on anti-human leukocyte antigen antibody detection assays. Transplantation 2007;84(258).
   PubMedGoogle Scholar
• Visentin J., Clinical impact of preformed donor specific denatured Class I HLA antibodies after kidney transplantation. Clin Transplant 2015:p. n/a-n/a.
   Web of Science ®Google Scholar
• El-Awar N., Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol 2009;70(10):844–853.
   PubMed Web of Science ®Google Scholar
• Grenzi P.C., Antibodies against denatured HLA class II molecules detected in luminex-single antigen assay. Hum Immunol 2013;74(10): 1300–1303.
   PubMed Web of Science ®Google Scholar
• Peacock S., Questioning the added value of Luminex single antigen beads to detect C1q binding donor HLA-specific antibodies. Transplantation 2014.
   PubMedGoogle Scholar
• Otten H.G., The significance of pretransplant donor-specific antibodies reactive with intact or denatured human leucocyte antigen in kidney transplantation. Clin Exp Immunol 2013;173(3):536–543.
   PubMed Web of Science ®Google Scholar
• Visentin J., Denatured Class I human leukocyte antigen antibodies in sensitized kidney recipients: Prevalence, relevance, and impact on organ allocation. Transplantation 2014;98(7):738–744. doi: 10.1097/TP.0000000000000229
   PubMed Web of Science ®Google Scholar
• Pereira S., Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol 2011 72(6):492–498.
   PubMed Web of Science ®Google Scholar
• Poli F., Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02:01: A case report. Hum Immunol 2011;72(11):p. 1045–1048.
   PubMed Web of Science ®Google Scholar
• McMurtrey C., Profiling antibodies to Class II HLA in transplant patient sera. Human Immunol, (0).
   Google Scholar
• Marrari M.D., RJ. Detection of donor-specific HLA antibodies before and after removal of a rejected kidney transplant. Transpl Immunol 2010 22(3-4):105–109.
   PubMed Web of Science ®Google Scholar
• El-Awar N., HLA class I epitopes: Recognition of binding sites by mAbs or eluted alloantibody confirmed with single recombinant antigens. Hum Immunol 2007;68(3): 170–180.
   PubMed Web of Science ®Google Scholar
• Focosi D., Clinical impact of anti-endothelial cell antibodies in kidney and pancreas transplantation. Enliven: Surg Transplant 2014;1(1):001.
   Google Scholar
• Arnold M.-L., Detection and specification of noncomplement binding anti-HLA alloantibodies. Human Immunol 2004;65(11):1288–1296.
   PubMed Web of Science ®Google Scholar
• Lobashevsky A., Subtypes of immunoglobulin (Ig)-G antibodies against donor class II HLA and cross-match results in three kidney transplant candidates. Transplant Immunol 2010;23(1-2): 81–85.
   PubMed Web of Science ®Google Scholar
• Hönger G., , C4d-fixing capability of low-level donor-specific HLA antibodies is not predictive for early antibody-mediated rejection. Transplantation 2010;89(12): 1471–1475. doi:10.1097/TP.0b013e3181dc13e7.
   PubMed Web of Science ®Google Scholar
• Smith J., C4d fixing, luminex binding antibodies—A new tool for prediction of graft failure after heart transplantation. Am J Transplant 2007;7(12): 2809–2815.
   PubMed Web of Science ®Google Scholar
• Wahrmann M., Clinical relevance of preformed C4d-fixing and non-C4d-fixing HLA single antigen reactivity in renal allograft recipients. Transplant International 2009;22(10):982–989.
   PubMed Web of Science ®Google Scholar
• Chen G., Sequeira F., Tyan D., Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads. Hum Immunol 2011;72(10):849–858.
   PubMed Web of Science ®Google Scholar
• Crespo M., Clinical relevance of pretransplant anti-HLA donor-specific antibodies: Does C1q-fixation matter? Transpl Immunol 2013
   PubMed Web of Science ®Google Scholar
• Yabu J.H. JP, C1q-fixing human leukocyte antigen antibodies are specific for predicting transplant glomerulopathy and late graft failure after kidney transplantation. Transplantation 2011;91(3): 342–347.
   PubMed Web of Science ®Google Scholar
• Loupy A., Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013;369(13): 1215–1226.
   PubMed Web of Science ®Google Scholar
• Sutherland S.M., Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant 2012;16(1):p. 12–17.
   PubMed Web of Science ®Google Scholar
• Kubal C.A., Crossmatch-positive liver transplantation in patients receiving thymoglobulin-rituximab induction. Transplantation 2014;97(1):p. 56–63.
   PubMed Web of Science ®Google Scholar
• O’Leary J.G., Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015: n/a-n/a.
   Web of Science ®Google Scholar
• D F., M D.D. ,and F P. Endogenous anti-C1q antibodies do not interfere with C1qScreen assay. Tissue Antigens, 2014.
   Google Scholar
• Hönger G., Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation 2011;92(1): 41–47. doi:10.1097/TP.0b013e31821cdf0d.
   PubMed Web of Science ®Google Scholar
• O’Leary J.G., Klintmalm G.B. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013;18(3): 279–284.
   PubMed Web of Science ®Google Scholar
• Kaneku H., Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012;18(8):984–992.
   PubMed Web of Science ®Google Scholar
• Liwski R., Anti-human globulin enhanced C1qScreen assay positivity correlates with CC-AHG crosmatch results. in ASHI. 2013. Chicago.
   Google Scholar
• Xia Y., Kellems R. Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Rev Clin Immunol 2011;7(7): 659–674.
   PubMed Web of Science ®Google Scholar
• Sigdel T., Non-HLA antibodies to immunogenic epitopes predict the evolution of chronic renal allograft injury. J Am Soc Nephrol 2012;23(4):750–763.
   PubMed Web of Science ®Google Scholar
• Regele H. Non-HLA antibodies in kidney allograft rejection: convincing concept in need of further evidence. Kidney Int 2011;79(6):583–586.
   PubMed Web of Science ®Google Scholar
• Opelz G., Study C.T. Non-HLA transplantation immunity revealed by lymphocytotoxic antibodies. Lancet 2005;365(9470):1570–1576.
   PubMed Web of Science ®Google Scholar
• Yang L., C4d deposition is correlated with the level of antivimentin antibody in rat kidneys undergoing chronic allograft nephropathy. Transplant Proc 2008;40(8):2786–2789.
   PubMed Web of Science ®Google Scholar
• Reinsmoen N., Anti-angiotensin type 1 receptor antibodies associated with antibody mediated rejection in donor HLA antibody negative patients. Transplantation 2010;90(12):1473–1477.
   PubMed Web of Science ®Google Scholar
• Kelsch R., Accelerated kidney transplant rejection and hypertensive encephalopathy in a pediatric patient associated with antibodies against angiotensin type 1 receptor and HLA class II. Transplantation 2011;92(10):p. e57–59.
   PubMed Web of Science ®Google Scholar
• Latif N., Association of pretransplantation antiheart antibodies with clinical course after heart transplantation. J Heart Lung Transplant 1995;14(1 Pt 1):119–126.
   PubMed Web of Science ®Google Scholar
• Jurcevic S., , Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001;71(7):886–892.
   PubMed Web of Science ®Google Scholar
• Nath D., Characterization of immune responses to cardiac self-antigens myosin and vimentin in human cardiac allograft recipients with antibody-mediated rejection and cardiac allograft vasculopathy. Journal of Heart and Lung Transplantation 2010;29(11): 1277–1285.
   PubMed Web of Science ®Google Scholar
• Nath D., A role for antibodies to human leukocyte antigens, collagen-V, and K-alpha1-Tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation 2011;91:1036.
   PubMed Web of Science ®Google Scholar
• Hiemann N., Non-HLA antibodies targeting vascular receptors enhance alloimmune response and microvasculopathy after heart transplantation. Transplantation 2012;94(9): 919–924.
   PubMed Web of Science ®Google Scholar
• Vermehren, D., Sumitran-Holgersson, S., Isolation of precursor endothelial cells from peripheral blood for donor-specific crossmatching before organ transplantation. Transplantation 2002;74(11):1479–1486.
   PubMed Web of Science ®Google Scholar
• Breimer M., Multicenter evaluation of a novel endothelial cell crossmatch test in kidney transplantation. Transplantation 2009;87(4): 549–556.
   PubMed Web of Science ®Google Scholar
• Alheim M., The outcome of the endothelial precursor cell crossmatch test in lymphocyte crossmatch positive and negative patients evaluated for living donor kidney transplantation. Hum Immunol 2013;74(11):1437–1444.
   PubMed Web of Science ®Google Scholar
• Sánchez-Zapardiel E., Harmful Effect of Preformed Anti-MICA Antibodies on Renal Allograft Evolution in Early Posttransplantation Period. Transplantation 2013;96(1): 70–78.
   PubMed Web of Science ®Google Scholar
• Dragun D., Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005;352(6):558–569.
   PubMed Web of Science ®Google Scholar
• Leong H.S., Vimentin autoantibodies induce platelet activation and formation of platelet-leukocyte conjugates via platelet-activating factor. J Leukoc Biol 2008;83(2): 263–271.
   PubMed Web of Science ®Google Scholar
• Youinou, P., Jamin, C. The miscellany of anti-endothelial cell autoantibodies. Isr Med Assoc J 2012;14(2): 119–120.
   PubMed Web of Science ®Google Scholar
• OneLambda. AT1R-Antibody ELISA. [cited 2014 Apr 29]; Available from: http://www.onelambda.com/product.aspx?c1=biomarker-detection&c2=at1r&c3=11&c4=35&c5=100.
   Google Scholar
• Sun Q., De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney Int 2011;79(6): 655–662.
   PubMed Web of Science ®Google Scholar
• Segerer S., The Duffy antigen receptor for chemokines is up-regulated during acute renal transplant rejection and crescentic glomerulonephritis. Kidney Int 2000;58(4):1546–1556.
   PubMed Web of Science ®Google Scholar
• Segerer S., When renal allografts turn DARC. Transplantation 2003;75(7):1030–1034.
   PubMed Web of Science ®Google Scholar
• Watorek E.B., M, Hałoń A., Klinger M. Anti-Fya antibodies as the cause of an unfortunate post-transplant course in renal transplant recipient. Ann Transplant 2008;13(1): 48–52.
   PubMed Web of Science ®Google Scholar
• Proust B., Unexpected anti-HLA-DR and -DQ alloantibodies after nephrectomy of an HLA-DR and -DQ identical first renal transplant. Transpl Immunol 2009;21(3): 166–168.
   PubMed Web of Science ®Google Scholar